Kyntra Bio (KYNB) EBT Margin (2014 - 2026)
Kyntra Bio's (KYNB) quarterly EBT Margin came in at 812.28% in Q2 2026, up 183416.0% year-over-year from N/an in Q2 2025, and up 300.65% quarter-over-quarter from 404.82% in Q1 2026.
Powered by 
Analysis
Kyntra Bio (KYNB) EBT Margin (2014 - 2026) Analysis & Trends
Kyntra Bio has disclosed EBT Margin across 13 years of filings, most recently posting 812.28% for Q2 2026.
- In Q2 2026, EBT Margin rose 183416.0% year-over-year to 812.28%; the TTM figure through Jun 2026 stood at 408.66% (up 78251.0% YoY), while the FY2025 annual figure was 905.19%, down 38742.0% from the prior year.
- EBT Margin came in at 812.28% for Q2 2026 at Kyntra Bio, up from 404.82% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 812.28% in Q2 2026 to a low of 39259.35% in Q3 2024.
- Average EBT Margin over 5 years is 2791.1%, with a median of 340.57% recorded in 2024.
- Year-over-year, EBT Margin plunged 3909937 bps in 2024 and soared 3803760 bps in 2025.
- Over 5 years, EBT Margin stood at 789.85% in 2022, then surged by 116 bps to 126.16% in 2023, then slumped by 319 bps to 276.33% in 2024, then tumbled by 314 bps to 1144.09% in 2025, then jumped by 171 bps to 812.28% in 2026.
- Per Business Quant data, the three most recent EBT Margin figures were 812.28% in Q2 2026, 404.82% in Q1 2026, and 1144.09% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.67 Bn | 192.69 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 180.06 Bn | 176.88 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 131.44 Bn | 123.59 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.95 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 60.28 Bn | 55.10 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 53.87 Bn | 48.73 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 33.15 Bn | 29.85 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.88 Bn | 30.60 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 29.16 Bn | 29.16 Bn | 1.16 Mn | -20,427.46% |
| 10 | Kyntra Bio | 32.30 Mn | 32.30 Mn | 1.47 Mn | 812.28% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 812.28% |
| Mar 31, 2026 | -404.82% |
| Dec 31, 2025 | -1,144.09% |
| Sep 30, 2025 | -1,221.75% |
| Jun 30, 2025 | -1,021.88% |
| Mar 31, 2025 | -612.05% |
| Dec 31, 2024 | -276.33% |
| Sep 30, 2024 | -39,259.35% |
| Jun 30, 2024 | -4,747.09% |
| Mar 31, 2024 | -193.34% |
| Dec 31, 2023 | 126.16% |
| Sep 30, 2023 | -159.98% |
| Jun 30, 2023 | -199.61% |
| Mar 31, 2023 | -214.12% |
| Dec 31, 2022 | -789.85% |
| Sep 30, 2022 | -584.32% |
| Jun 30, 2022 | -245.47% |
| Mar 31, 2022 | -104.25% |
| Dec 31, 2021 | -811.88% |
| Sep 30, 2021 | 31.78% |